Alexion Pharmaceuticals Takes on Amyloidosis with Caelum Biosciences

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 2 (Table of Contents)

Published: 14 Feb-2019

DOI: 10.3833/pdr.v2019.i2.2407     ISSN: 1756-7874

Section: Research & Development



In its first foray in treating light chain (AL) amyloidosis, Alexion Pharmaceuticals has purchased an equity stake in Caelum Biosciences and gained an option to acquire the company based on Phase II data for Caelum’s lead asset, CAEL-101...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details